A new version of the Cefaly migraine therapy device is coming to market. The Cefaly II is a much smaller iteration of the first FDA-approved device intended to help prevent the onset of migraines.
The Cefaly delivers transcutaneous electrical stimulation to the trigeminal nerve, which is known to be involved with the pathophysiology of some migraines. Twenty minutes of therapy with the Cefaly has been shown to reduce migraine headaches.
The Cefaly II sticks straight to the forehead with an adhesive electrode pad to which the actual generator is clipped on magnetically. A button on the front of the device allows patients to ramp up the intensity of the stimulation to their preferred liking.
The new Cefaly II now sports a rechargeable battery, and it can be charged via any standard USB port.
The Cefaly still requires a physician’s prescription, but the potential discovered side effects have been pretty minimal.
Here’s a quick presentation showing the new Cefaly II:
Product page: Cefaly…